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Abstract
Insulin is an essential hormone produced by β-cells in the pancreas. The release of insulin
is tightly regulated in healthy people in order to control blood sugar level in our body.
However, people with Type 2 Diabetes have insufficient insulin secretion from pancreatic
β-cells, leaving to high blood sugar (hyperglycemia) and β-cell failure. microRNAs
(miRNAs or miR) are newly discovered small regulatory molecules and have emerged as
important regulator of cell growth, differentiation, and organ function. Altered miRNA
function has been implicated in the pathogenesis of a variety of human disease, including
diabetes. In this report, we focus on dissecting the physiologic function of miR-483 in
regulating insulin secretion and preventing β-cell failure. We discovered that miR-483
deletion in β-cells significantly decreased insulin secretion, leading to glucose
intolerance when the mice were challenged with a high-fat diet. Mouse genotyping,
quantitative real-time PCR, blood glucose and insulin assays, along with glucose
tolerance testing have been applied in the study.
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1 Introduction
1.1 Diabetes mellitus and Pancreatic Beta-Cells
Diabetes mellitus, more broadly known as diabetes, is a chronic disease associated with
abnormally high levels of sugar (glucose) in the blood. The blood glucose level is tightly
controlled by insulin, a hormone produced by the pancreas. Absence or insufficient
production of insulin, or an inability of the body to properly use insulin causes diabetes.
As stated by the World Health Organization (WHO), last updated in 2014, diabetes
affects roughly 422 million people throughout the world today. One of the most
important issues regarding diabetes is it’s damaging effects on other body parts such as
the brain, kidneys, and heart through prolonged hyperglycemic conditions and the stress
these conditions cause on the body. Such potential consequences are increased risks of
stroke, heart attack, and lower limb amputations. All of the above information can be
seen in Figure 1 below.
There are two major types of diabetes: type 1 and type 2 diabetes. Type 1 diabetes (T1D)
is generally associated with immune-mediated destruction of pancreatic β-cells (1) which
are cells found in pancreatic islets that synthesize and release insulin in response to glucose
in the blood. Unfortunately, there is no known cause that underlies this destruction of the
β-cells. While it can be diagnosed at any age, T1D is generally diagnosed in childhood
between the ages of five and seven. Type 2 diabetes (T2D) on the other hand, is more
associated with overall insulin insensitivity due to insulin resistance (2). Along with insulin
resistance both types of diabetes lead to an overall hyperglycemic condition of the body.
As the risks increase with the length of the hyperglycemic conditions, there are a variety
of methods to treat the symptoms that come with diabetes. Such methods as maintaining
“normal” blood glucose levels through meticulous observation and insulin pumps are
common for diabetics. However, currently diabetes is still categorized as a chronic disease
with no known cure as per the WHO.
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Figure 1. Classification of types of diabetes, its consequences, and its prevalence
worldwide (11).
Pancreatic β-cells are the cell type that produces insulin and allows the body to maintain a
regulated blood glucose level. In patients with T1D or T2D, β-cell mass and function are
damaged, leading to insufficient insulin secretion such as in T1D or the non-effective use
of insulin due to insulin resistance as in T2D. This, in turn, leads to hyperglycemia or
hyperglycemic conditions overall (3). Due to these cells having such a large impact on
diabetes they are often the target for various studies that revolve around insulin secretion
and gene expression in diabetes.
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1.2 Role of microRNAs in Pancreatic Beta Cells
While many transcription factors and signal proteins are most commonly involved in
determining β-cell function, epigenetic regulation including microRNAs (miRNAs)
introduces additional layers of temporal and spatial control that can modify β-cell
function. miRNAs are small double stranded non-coding RNAs that are about 21-24
nucleotides in length (4). miRNAs act as negative regulators of gene expression by either
inhibiting the translation of messenger RNAs (mRNAs) or destabilizing them. While the
first miRNA was discovered long ago (1993) in C. elegans (5), many more have been
discovered since then. As per miRBase, a microRNA database, there are a total of 38,589
miRNAs that have currently been discovered as of October 2018.
miRNAs work by targeting the 3’-UTR (untranslated region) in animal mRNA and the
coding regions of mRNA in plants. Through their targeting of these mRNAs they are able
to effectively prevent subsequent protein formation, and therefore gene expressions (6).
That being said, studying them is made harder as miRNAs can target many mRNAs.
Essentially the target miRNA one studies may impact other areas of the body. Currently
there are many miRNAs that have been documented to relate to glucose homeostasis
whether that be through insulin secretion or beta-cell mass. Some of these miRNAs can be
seen in Figure 2.

Figure 2. Crosstalk of miRNAs between tissues in glucose homeostasis regulation (9).
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More recently however, there has been some headway made in the understanding of what
miRNAs do and what they could be used for in regard to treatment methods. For
example, one of the most important miRNAs with regards to pancreatic β-cells is
miRNA-375. This miRNA is responsible for maintaining correct beta-cell mass and if
beta-cells have less mass less insulin is made, resulting in a higher likelihood of diabetic
symptoms (7). That being said there are plenty more that are able to regulate aspects such
as insulin secretion, β-cell proliferation, and apoptosis.
A more recent miRNA that is being studied is that of miRNA-483. This miRNA is
believed to have potential roles in beta cell mass and would offer another miRNA in the
overall regulation of genes that impact hyperglycemic conditions. The reasoning for this
is that the miRNA, more specifically miRNA-483-3p, has been observed to be highly
upregulated in pancreatic cancer patients (8). Therefore, a better understanding is needed
to determine the effects both upregulating and downregulating the miRNA will do,
especially in cases pertaining to diabetes.
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2 Materials and Methods
2.1 Animal Generation
The miR-483 floxed mice were produced at the inGenious Targeting Laboratory,
Ronkonkoma, NY (www.genetargeting.com). Mice with a pancreatic beta-cell-specific
deletion of miR-483 were generated by crossing miR-483 floxed mice with Ins1-Cre
mice (Stock # 026801; The Jackson Laboratory) the target for knockout can be seen in
Figure 3. Genotyping of all mice was performed by PCR using DNA from mouse finger
biopsy. Gene specific primers are summarized in Table 1. All mice were housed in a
pathogen-free animal facility, maintained on a 12-hour light/12-hour dark cycle and had
free access to either regular chow diet or high-fat-diet containing 60% kCal fat (Research
Diets) after weaning (4weeks). All the procedures were approved by the Animal Care
Committee at Michigan Technological University.
Table 1. . PCR master mix components for mouse genotyping. Master mix 1 contained
components necessary for INS-Cre mouse genotyping, while Master Mix 2 for miR-483
knockout mouse genotyping.
Master Mix 1

Master Mix 2

Go-taq Green: 10 µl

Go-taq Green: 10µl

Cre Forward Primer: 0.5 µl

483 Forward Primer: 1µl

Cre Reverse Primer: 0.5 µl

483 Reverse Primer: 1 µl

RNase free Water: 7 µl

RNase free water: 6 µl

Total: 18 µl

Total: 18 µl
Mater mix total = total * (Samples + NC + PC + 1). NC = negative
control, PC = positive control, and add 1 with the samples to ensure
enough is made for PCR.
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Figure 3.Structure of miR-483 floxed construct. The WT region of IGF2-miR483 gene
locus is separated into three arms; long-arm (LA), middle-arm (MA), and short-arm (SA).
The targeted DNA sequence contains an iNeo cassete with two sites of loxP and FRT
recognition sites. These are located right after the miR-483 sequence in the second intron
of the IGF2 host gene.

2.2 Islet Isolation
Pancreatic islets were isolated and purified by common bile duct perfusion of collagenase
V (0.6 mg/ml) following the protocol described (10). The islets were digested in 2 mg
collagenase in Hanks buffer saline for 7 minutes. The purified islets were cultured in
RPMI 1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin for 24
to 72 hours according to the experiments.

2.3 Quantitative real-time PCR for miRNA
Total RNA from islets or cell lines was extracted using miRNeasy kit (Qiagen) according
to the manufacturer's instructions and treated with rDNase I (Qiagen). TaqMan miRNA
qPCR detection system (applied Biosystem) was used for quantification of miR-483.
Quantitative real-time PCR (RT-qPCR) was performed using Power SYBR Green PCR
Master Mix (Applied Biosystem). Real-time PCR was performed on a StepOnePlus™
System (Applied biosystem) using the following program: 10 min at 95 °C for activation
of reverse DNA polymerase and 40 cycles of 95 °C for 15 sec, 60 °C for 1 min. All
6

samples were run in duplicate, and the RNA expression was determined using relative
comparison method (∆∆Ct), with actin mRNA as an internal standard.

2.4 Body weight, Blood Glucose and Plasma Insulin
Measurements
Mouse body weight was measured on a simple electronic scale. Blood glucose levels
were taken by cutting off the very tip of the mouse tail and taking a blood sample. Blood
glucose measurement was then taken by a glucose measurement device (ReliOn). Plasma
insulin measurements were done by using the Ultrasensitive Insulin ELISA kit (Crystal
Chem).

2.5 Glucose Tolerance Test
Glucose tolerance testing was carried out by fasting the mice for 16 hours prior to
glucose injection. Mice were intraperitoneally (i.p.) injected with glucose in saline at 1.0
g/kg body weight. Plasma glucose levels were measured after 0, 15, 30, 45, 60, 90 and
120 min from tail vein blood.
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3 Results
3.1 Confirmation of Mouse Genotypes
Mouse genotypes were confirmed using PCR and subsequent gel electrophoresis. As
shown in Figure 4 the results are based upon previous samples acting as a positive control
to know which bands are “lower” or “upper” bands. The distinction between having these
two bands is important for future experiments as a mouse’s genotype can determine
which experiments it undergoes. In addition to having a well that displays whether or not
the 483 sequence is apparent, the gel also determines whether the mouse expresses InsCre or not.

Figure 4. Mouse genotyping by PCR . The floxed miR-483 mice (miR483fl/fl) were
crossed with Ins1-Cre mice, transgenic mice expressing Cre recombinase driven by
mouse ins1 promoter to generate β-cell specific knockout mice (miR483
Once genotypes are obtained and confirmed via gel electrophoresis the mice can then be
separated based upon the tests that are needed to be run. Whether they are tested on high
fat diets or normal chow diets depends on the genotype of the mouse. In addition to gel
electrophoresis a table of genotypes, sex, ear tag, etc. was made in order to keep mice
differentiated between one another. This differentiation and data keeping can be seen in
Table 2.
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Table 2. An example of how data is kept in the lab to ensure data is handled well. DOB
means date of birth. Ear Tags are not actual for these mice, placeholders are used instead.
miR-483 -/- means the mice was a double knockout for 483, while miR-fl/fl means the
mouse was floxed.
DOB:
1/17/2020

Number

Sex

Genotype

Ear Tag

879-7

M

miR-483 -/-

75L

879-8

F

miR-483 -/-

86R

879-9

F

miR-483 -/-

98L

879-10

F

mir-483 fl/fl

99L

879-11

M

miR-483 -/-

76R

879-12

F

miR-483 -/-

77R

879-13

F

miR-483 -/-

84L

879-14

F

miR-483 -/-

85R

879-15

M

mir-483 fl/fl

96L

879-16

M

mir-483 fl/fl

74R

879-1/-4

M

miR-483 -/-

80L

3.2 Quantitative real-time PCR of miRNA Analysis
MicroRNA analysis was done through the use of real-time PCR methods. This allowed
for an accurate representation and confirmation of miRNAs within the tissues that were
being tested. Through the confirmation, real-time PCR was used to make comparisons
between knockout mice and non-knockout mice. Figure 5 shows an example of results
obtained from qPCR.
To validate miR-483 expression in miR-483 knockout mice, we isolated islets from miR483 KO mice (miR-483-/-) and control mice (Ins-Cre). Compared to control mice, the
expression of miR-483 was significantly decreased in isolated islets of miR-483KO mice
confirmed by RT-qPCR. The results indicated that miR-483 was knock out successfully
(Fig 5 ).
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Figure 5. Confirmation of miR-483 knockout by RT-qPCR in islets isolated from miR483-/- and Cre control mice. (** p < 0.01 vs. Cre).

3.3 Glucose Tolerance Test Analysis
Glucose tolerance testing (GTT) was done in order to complete reverse genetics and see
the genotype to phenotype differences between the mice. Figure 6 shows results and
subsequent analysis for the GTT and the selected mice.
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Figure 6. A. miR-483 deficiency increased high-fat-diet-induced glucose intolerance. A.
Following 14 weeks of high fat diet (HFD), GTT was completed for 20-week-old male
mice with genotype Cre versus miRNA-483 -/- (n=15-17 and *p<0.05 or **p<0.01). B.
Area under the curve (AUC) calculated for the quantification of the GTT curve.
From the GTT results it was seen that the Cre, or wild type (WT) mice, had an easier time
taking the glucose after injection and getting back to normal glucose levels, therefore
making the WT mice have a better glucose tolerance overall. In addition, it is also shown
that the double knockout mice (miR-483 -/-) had a worse glucose tolerance as the curve
increases more at the 30 minutes mark before staying higher than the WT mice and
lowering back down at the 120-minute mark. From this information one can say that the
mice that were double knockout could have a lower tolerance for glucose, which makes
them more susceptible to develop hyperglycemic conditions and subsequent diabetes.
With that information future experiments for GTT and β-cell mass can be conducted in
order to fill the overall picture for the effect’s miRNA-483 has on pancreatic β-cells.
These results are again confirmed in the area under the curve (AUC) graph in Figure 7.
Overall there is a significant difference between the Cre and miR-483 -/- mice in their
overall glucose tolerance. As shown the miR-483 -/- mice had a larger AUC when
compared to the Cre mice, confirming what was seen in Figure 6A. Figure 7 is provided
to show the differences between insulin levels and confirm GTT results. The figure
shows a significant difference between the plasma insulin levels of the mice at the 30minute mark in the GTT test. The Cre mice have a higher level of plasma insulin
meaning their pancreas is secreting insulin to deal with the glucose in the bloodstream.
This means that the mice will have a higher glucose tolerance as their bodies are able to
secrete insulin to deal with the glucose.
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Figure 7. Plasma insulin concentration taken after 30 minutes following glucose injection
(*p<0.05).
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4 Discussion
The methods and results shown in this report go a long way to helping confirm the
interactions miRNA-483 has upon pancreatic β-cells and in the prolonging of
hyperglycemic conditions. While the claims cannot be set-in-stone yet, it is possible to
show through GTT and qPCR that there are distinctive differences between those who
have normal miRNA-483 expression and those that have less. For example, as shown in
the qPCR results, we were able to confirm that the mouse was indeed a knockout (KO)
for 483 due to the lower relative expression in comparison to the WT Cre mice. Although
there is still some expression of miRNA-483 shown, this is due to other cells in the
pancreas (such as α-cells) expressing the miRNA. With that being the case, it is possible
to say that the KO mouse was successful due to the expression being so much lower.
In addition to the confirmation in qPCR, the claims can be primarily confirmed through
the genotypic to phenotypic differences in glucose tolerance and insulin secretion
between the mice. Mice that were knockouts for miRNA-483 had lower tolerance, or
were more intolerant, to glucose through its higher AUC and lower plasma insulin when
compare to the WT (Cre) mice. This data supports the claim that miRNA-483 is involved
in insulin secretion and overall insulin resistance in the mouse, which can lead to
hyperglycemic conditions in the mice.
Possibly the most important factor in figuring out what genotype leads to what phenotype
is the genotyping of the mice. Without proper genotyping methods and ways to confirm
the genotypes of the mice, one would be unable to do any subsequent analysis or
experiments as the genotypes could be incorrect. In addition, without proper genotyping
methods there would be many inconsistencies in finalized data, therefore it was good to
be able to confirm the genotypes of the mice during many occasions. In the case for these
experiments the genotyping was confirmed through multiple PCR and gel electrophoresis
as needed. This meant that if there were any issues in PCR, DNA isolation, or gel
electrophoresis the experiments would need to be run again and again in order to confirm
validity. This occurred a few times over the course of the experiments and figuring out
what the issue was always aided in present and future genotyping experiments.
For future experiments it would be good to confirm and finalize claims made surrounding
miRNA-483 and its effects on pancreatic β-cells. Through more glucose tolerance testing
of mice at varying ages and diets we can confirm the results obtained and say that the
miRNA impacts insulin secretion and glucose tolerance in mice. From this we can then
say that something similar in humans is possible and can look for ways to not only study
the miRNA in humans but make treatment and diagnosis methods more available. In
addition, it would also be good to see how the miRNA impacts other tissues in the body
for a more generalized understanding in the case that they can be used as biomarkers for
diagnosis or for further treatment methods.
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